Nlrp3 is a key modulator of diet-induced nephropathy and renal cholesterol accumulation

Kidney International

Volumn 85, Issue 5, 2014, Pages 1112-1122

  Bakker, Pieter J ^a   Butter, Loes M ^a   Kors, Lotte ^a   Teske, Gwendoline J D ^a   Aten, Jan ^a   Sutterwala, Fayyaz S ^b   Florquin, Sandrine ^a,c   Leemans, Jaklien C ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF IOWA   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic nephropathy; Dyslipidemia; Immunology and pathology; Obesity

Indexed keywords

CRYOPYRIN; FRUCTOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; BIOLOGICAL MARKER; CARBOHYDRATE DIET; CARRIER PROTEIN; CHOLESTEROL INTAKE; CIAS1 PROTEIN, MOUSE; INFLAMMASOME; SREBF2 PROTEIN, MOUSE;

ABDOMINAL OBESITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DYSLIPIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FIBROSIS; MACROPHAGE MIGRATION; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; STEATOSIS; WEIGHT GAIN; ANIMAL; BLOOD; C57BL MOUSE; CARBOHYDRATE DIET; CHOLESTEROL INTAKE; COMPARATIVE STUDY; DISEASE MODEL; FIBROSIS; GENETICS; IMMUNOLOGY; KIDNEY; KIDNEY DISEASES; KNOCKOUT MOUSE; LIPID DIET; MACROPHAGE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; WESTERN DIET;

ANIMALS; BIOLOGICAL MARKERS; CARRIER PROTEINS; CHOLESTEROL, DIETARY; DIET, HIGH-FAT; DIET, WESTERN; DIETARY CARBOHYDRATES; DISEASE MODELS, ANIMAL; FIBROSIS; FRUCTOSE; INFLAMMASOMES; KIDNEY; KIDNEY DISEASES; MACROPHAGES; MALE; METABOLIC SYNDROME X; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

EID: 84899934630     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.503     Document Type: Article

References (61)

1. Lakka H-M, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
2. Lorenzo C, Okoloise M, Williams K et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26: 3153-3159.
3. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140.
4. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550-562.
5. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174.
6. Heidemann C, Schulze MB, Franco OH et al. Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all causes in a prospective cohort of women. Circulation 2008; 118: 230-237.
7. Stanhope KL. Role of fructose-containing sugars in the epidemics of obesity and metabolic syndrome. Annu Rev Med 2012; 63: 329-343.
8. Jiang T, Wang Z, Proctor G et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 2005; 280: 32317-32325.
9. Odermatt A. The Western-style diet: a major risk factor for impaired kidney function and chronic kidney disease. Am J Physiol Renal Physiol 2011; 301: F919-F931.
10. Cirillo P, Gersch MS, Mu W et al. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol 2009; 20: 545-553.
11. Gersch MS, Mu W, Cirillo P et al. Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Renal Physiol 2007; 293: F1256-F1261.
12. Thomas G, Sehgal AR, Kashyap SR et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6: 2364-2373.
13. Konner AC, Bruning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab 2011; 22: 16-23.
14. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-426.
15. Iyer SS, Pulskens WP, Sadler JJ et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA 2009; 106: 20388-20393.
16. Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3 inflammasome. Immunol Rev 2011; 243: 152-162.
17. Stienstra R, van Diepen JA, Tack CJ et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA 2011; 108: 15324-15329.
18. Stienstra R, Joosten LaB, Koenen T et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010; 12: 593-605.
19. Vandanmagsar B, Youm Y-HH, Ravussin A et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
20. Zhou R, Tardivel A, Thorens B et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-140.
21. Wang C, Pan Y, Zhang Q-Y et al. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One 2012; 7: e38285.
22. Hu Q-H, Zhang X, Pan Y et al. Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructosefed rats. Biochem Pharmacol 2012; 84: 113-125.
23. Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int 2008; 73: 1216-1219.
24. Haller H, Dragun D, Miethke A et al. Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int 1996; 50: 473-480.
25. Hill PA, Lan HY, Nikolic-Paterson DJ et al. ICAM-1 directs migration and localization of interstitial leukocytes in experimental glomerulonephritis. Kidney Int 1994; 45: 32-42.
26. Brown WJ, Sullivan TR, Greenspan P. Nile red staining of lysosomal phospholipid inclusions. Histochemistry 1992; 97: 349-354.
27. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 2002; 110: 905-912.
28. Tabas I. Cholesterol in health and disease. J Clin Invest 2002; 110: 583-590.
29. Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim Biophys Acta 2000; 1529: 164-174.
30. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131.
31. Grundy SM. Multifactorial causation of obesity: implications for prevention. Am J Clin Nutr 1998; 67: 563S-572SS.
32. Kuczmarski RJ, Flegal KM, Campbell SM et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272: 205-211.
33. Enhö rning S, Bankir L, Bouby N et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond) 2013; 37: 598-603.
34. Shigeoka Aa, Mueller JL, Kambo A et al. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol 2010; 185: 6277-6285.
35. Day Y-J, Huang L, Ye H et al. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol 2005; 288: F722-F731.
36. Ko GJ, Boo C-S, Jo S-K et al. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 2008; 23: 842-852.
37. Chow F, Ozols E, Nikolic-Paterson DJ et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004; 65: 116-128.
38. Yuan Y, Verna LK, Wang NP et al. Cholesterol enrichment upregulates intercellular adhesion molecule-1 in human vascular endothelial cells. Biochim Biophys Acta Mol Cell Biol Lipids 2001; 1534: 139-148.
39. Glushakova O, Kosugi T, Roncal C et al. Fructose induces the inflammatory molecule ICAM-1 in endothelial cells. J Am Soc Nephrol 2008; 19: 1712-1720.
40. Schwartz YS, Dushkin MI, Komarova NI et al. Cholesterol-induced stimulation of postinflammatory liver fibrosis. Bull Exp Biol Med 2008; 145: 692-695.
41. Teratani T, Tomita K, Suzuki T et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 2012; 142: 152-164e10.
42. Yokoi H, Mukoyama M, Nagae T et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004; 15: 1430-1440.
43. Ito Y, Aten J, Bende RJ et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998; 53: 853-861.
44. Sánchez-López E, Rayego S, Rodrigues-D?́ez RR et al. CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NFkappaB. J Am Soc Nephrol 2009; 20: 1513-1526.
45. Cicha I, Goppelt-Struebe M. Connective tissue growth factor: contextdependent functions and mechanisms of regulation. Biofactors 35: 200-208.
46. Moorhead J, El-Nahas M, Chan M et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 1309-1311.
47. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 2009; 5: 713-721.
48. Nakagawa T, Cirillo P, Sato W et al. The conundrum of hyperuricemia, metabolic syndrome, and renal disease. Intern Emerg Med 2008; 3: 313-318.
49. Gurcel L, Abrami L, Girardin S et al. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 2006; 126: 1135-1145.
50. Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab 2012; 16: 414-419.
51. Xiao H, Lu M, Lin TY et al. SREBP2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation 2013; 128: 632-642.
52. Martinon F, Pé trilli V, Mayor A et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.
53. Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
54. Menu P, Pellegrin M, Aubert J-F et al. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis 2011; 2: e137.
55. Wen H, Gris D, Lei Y et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
56. Masters SL, Dunne A, Subramanian SL et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
57. Sutterwala FS, Ogura Y, Szczepanik M et al. Critical role for NALP3/CIAS1/ Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006; 24: 317-327.
58. Bray Ga, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004; 79: 537-543.
59. Jü rgens H, Haass W, Castaneda TR et al. Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res 2005; 13: 1146-1156.
60. Pulskens WP, Teske GJ, Butter LM et al. Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injuryZimmer J (ed) PLoS One 2008; 3: 9.
61. Stroo I, Stokman G, Teske GJD et al. Chemokine expression in renal ischemia/reperfusion injury is most profound during the reparative phase. Int Immunol 2010; 22: 433-442.